Financhill
Sell
39

BNGO Quote, Financials, Valuation and Earnings

Last price:
$3.84
Seasonality move :
0.98%
Day range:
$3.71 - $3.94
52-week range:
$2.68 - $72.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.09x
P/B ratio:
0.34x
Volume:
44.6K
Avg. volume:
164.3K
1-year change:
-93.03%
Market cap:
$11.9M
Revenue:
$30.8M
EPS (TTM):
-$4.48

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BNGO
Bionano Genomics
$6.3M -$8.40 -9.75% -95.03% $7.00
AKYA
Akoya Biosciences
$19.3M -$0.23 10.01% -62.5% $2.65
AZTA
Azenta
$140.8M $0.07 -13.41% 86.12% $41.00
BRKR
Bruker
$772.5M $0.44 1.95% 880.84% $56.59
HBIO
Harvard Bioscience
$19.2M -$0.04 -19.63% -68.18% $4.50
KMTS
Kestra Medical Technologies
$15.7M -$0.53 -- -- $27.50
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BNGO
Bionano Genomics
$3.85 $7.00 $11.9M -- $0.00 0% 0.09x
AKYA
Akoya Biosciences
$1.14 $2.65 $56.8M -- $0.00 0% 0.69x
AZTA
Azenta
$27.71 $41.00 $1.3B -- $0.00 0% 2.10x
BRKR
Bruker
$40.51 $56.59 $6.1B 77.90x $0.05 0.49% 1.77x
HBIO
Harvard Bioscience
$0.30 $4.50 $13.4M -- $0.00 0% 0.14x
KMTS
Kestra Medical Technologies
$22.63 $27.50 $1.1B -- $0.00 0% 22.62x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BNGO
Bionano Genomics
23.43% -0.388 37.24% 0.86x
AKYA
Akoya Biosciences
90.93% 0.070 67.11% 1.66x
AZTA
Azenta
-- 2.222 -- 2.16x
BRKR
Bruker
53.77% 0.828 33.24% 0.66x
HBIO
Harvard Bioscience
36.85% 2.159 39.74% 0.35x
KMTS
Kestra Medical Technologies
-- 0.000 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BNGO
Bionano Genomics
-$8.4M -$22.6M -121.16% -158.95% -727.05% -$13.3M
AKYA
Akoya Biosciences
$14.4M -$5.7M -54.44% -212.99% -26.34% -$4M
AZTA
Azenta
$65.9M -$12.6M -3.48% -3.48% -8.77% $7M
BRKR
Bruker
$391.2M $65.7M 2.11% 4.53% 4.77% $39M
HBIO
Harvard Bioscience
$14M -$1.4M -11.92% -18.36% 5.88% $1.3M
KMTS
Kestra Medical Technologies
-- -- -- -- -- --

Bionano Genomics vs. Competitors

  • Which has Higher Returns BNGO or AKYA?

    Akoya Biosciences has a net margin of -728.57% compared to Bionano Genomics's net margin of -38.41%. Bionano Genomics's return on equity of -158.95% beat Akoya Biosciences's return on equity of -212.99%.

    Company Gross Margin Earnings Per Share Invested Capital
    BNGO
    Bionano Genomics
    -139.08% -$0.52 $63.8M
    AKYA
    Akoya Biosciences
    67.42% -$0.17 $83.8M
  • What do Analysts Say About BNGO or AKYA?

    Bionano Genomics has a consensus price target of $7.00, signalling upside risk potential of 81.82%. On the other hand Akoya Biosciences has an analysts' consensus of $2.65 which suggests that it could grow by 132.46%. Given that Akoya Biosciences has higher upside potential than Bionano Genomics, analysts believe Akoya Biosciences is more attractive than Bionano Genomics.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNGO
    Bionano Genomics
    0 2 0
    AKYA
    Akoya Biosciences
    0 8 0
  • Is BNGO or AKYA More Risky?

    Bionano Genomics has a beta of 2.367, which suggesting that the stock is 136.713% more volatile than S&P 500. In comparison Akoya Biosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BNGO or AKYA?

    Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akoya Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics pays -- of its earnings as a dividend. Akoya Biosciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BNGO or AKYA?

    Bionano Genomics quarterly revenues are $6.1M, which are smaller than Akoya Biosciences quarterly revenues of $21.3M. Bionano Genomics's net income of -$44.2M is lower than Akoya Biosciences's net income of -$8.2M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Akoya Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.09x versus 0.69x for Akoya Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNGO
    Bionano Genomics
    0.09x -- $6.1M -$44.2M
    AKYA
    Akoya Biosciences
    0.69x -- $21.3M -$8.2M
  • Which has Higher Returns BNGO or AZTA?

    Azenta has a net margin of -728.57% compared to Bionano Genomics's net margin of -28.21%. Bionano Genomics's return on equity of -158.95% beat Azenta's return on equity of -3.48%.

    Company Gross Margin Earnings Per Share Invested Capital
    BNGO
    Bionano Genomics
    -139.08% -$0.52 $63.8M
    AZTA
    Azenta
    45.94% -$0.88 $1.7B
  • What do Analysts Say About BNGO or AZTA?

    Bionano Genomics has a consensus price target of $7.00, signalling upside risk potential of 81.82%. On the other hand Azenta has an analysts' consensus of $41.00 which suggests that it could grow by 47.96%. Given that Bionano Genomics has higher upside potential than Azenta, analysts believe Bionano Genomics is more attractive than Azenta.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNGO
    Bionano Genomics
    0 2 0
    AZTA
    Azenta
    1 5 0
  • Is BNGO or AZTA More Risky?

    Bionano Genomics has a beta of 2.367, which suggesting that the stock is 136.713% more volatile than S&P 500. In comparison Azenta has a beta of 1.638, suggesting its more volatile than the S&P 500 by 63.767%.

  • Which is a Better Dividend Stock BNGO or AZTA?

    Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BNGO or AZTA?

    Bionano Genomics quarterly revenues are $6.1M, which are smaller than Azenta quarterly revenues of $143.4M. Bionano Genomics's net income of -$44.2M is lower than Azenta's net income of -$40.5M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.09x versus 2.10x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNGO
    Bionano Genomics
    0.09x -- $6.1M -$44.2M
    AZTA
    Azenta
    2.10x -- $143.4M -$40.5M
  • Which has Higher Returns BNGO or BRKR?

    Bruker has a net margin of -728.57% compared to Bionano Genomics's net margin of 2.17%. Bionano Genomics's return on equity of -158.95% beat Bruker's return on equity of 4.53%.

    Company Gross Margin Earnings Per Share Invested Capital
    BNGO
    Bionano Genomics
    -139.08% -$0.52 $63.8M
    BRKR
    Bruker
    48.82% $0.11 $4B
  • What do Analysts Say About BNGO or BRKR?

    Bionano Genomics has a consensus price target of $7.00, signalling upside risk potential of 81.82%. On the other hand Bruker has an analysts' consensus of $56.59 which suggests that it could grow by 39.7%. Given that Bionano Genomics has higher upside potential than Bruker, analysts believe Bionano Genomics is more attractive than Bruker.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNGO
    Bionano Genomics
    0 2 0
    BRKR
    Bruker
    6 7 0
  • Is BNGO or BRKR More Risky?

    Bionano Genomics has a beta of 2.367, which suggesting that the stock is 136.713% more volatile than S&P 500. In comparison Bruker has a beta of 1.228, suggesting its more volatile than the S&P 500 by 22.782%.

  • Which is a Better Dividend Stock BNGO or BRKR?

    Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.49% to investors and pays a quarterly dividend of $0.05 per share. Bionano Genomics pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BNGO or BRKR?

    Bionano Genomics quarterly revenues are $6.1M, which are smaller than Bruker quarterly revenues of $801.4M. Bionano Genomics's net income of -$44.2M is lower than Bruker's net income of $17.4M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Bruker's PE ratio is 77.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.09x versus 1.77x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNGO
    Bionano Genomics
    0.09x -- $6.1M -$44.2M
    BRKR
    Bruker
    1.77x 77.90x $801.4M $17.4M
  • Which has Higher Returns BNGO or HBIO?

    Harvard Bioscience has a net margin of -728.57% compared to Bionano Genomics's net margin of 0.07%. Bionano Genomics's return on equity of -158.95% beat Harvard Bioscience's return on equity of -18.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    BNGO
    Bionano Genomics
    -139.08% -$0.52 $63.8M
    HBIO
    Harvard Bioscience
    57.06% -- $100.3M
  • What do Analysts Say About BNGO or HBIO?

    Bionano Genomics has a consensus price target of $7.00, signalling upside risk potential of 81.82%. On the other hand Harvard Bioscience has an analysts' consensus of $4.50 which suggests that it could grow by 1377.35%. Given that Harvard Bioscience has higher upside potential than Bionano Genomics, analysts believe Harvard Bioscience is more attractive than Bionano Genomics.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNGO
    Bionano Genomics
    0 2 0
    HBIO
    Harvard Bioscience
    1 1 0
  • Is BNGO or HBIO More Risky?

    Bionano Genomics has a beta of 2.367, which suggesting that the stock is 136.713% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.441, suggesting its more volatile than the S&P 500 by 44.128%.

  • Which is a Better Dividend Stock BNGO or HBIO?

    Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BNGO or HBIO?

    Bionano Genomics quarterly revenues are $6.1M, which are smaller than Harvard Bioscience quarterly revenues of $24.6M. Bionano Genomics's net income of -$44.2M is lower than Harvard Bioscience's net income of $18K. Notably, Bionano Genomics's price-to-earnings ratio is -- while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.09x versus 0.14x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNGO
    Bionano Genomics
    0.09x -- $6.1M -$44.2M
    HBIO
    Harvard Bioscience
    0.14x -- $24.6M $18K
  • Which has Higher Returns BNGO or KMTS?

    Kestra Medical Technologies has a net margin of -728.57% compared to Bionano Genomics's net margin of --. Bionano Genomics's return on equity of -158.95% beat Kestra Medical Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BNGO
    Bionano Genomics
    -139.08% -$0.52 $63.8M
    KMTS
    Kestra Medical Technologies
    -- -- --
  • What do Analysts Say About BNGO or KMTS?

    Bionano Genomics has a consensus price target of $7.00, signalling upside risk potential of 81.82%. On the other hand Kestra Medical Technologies has an analysts' consensus of $27.50 which suggests that it could grow by 21.52%. Given that Bionano Genomics has higher upside potential than Kestra Medical Technologies, analysts believe Bionano Genomics is more attractive than Kestra Medical Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNGO
    Bionano Genomics
    0 2 0
    KMTS
    Kestra Medical Technologies
    4 1 0
  • Is BNGO or KMTS More Risky?

    Bionano Genomics has a beta of 2.367, which suggesting that the stock is 136.713% more volatile than S&P 500. In comparison Kestra Medical Technologies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BNGO or KMTS?

    Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kestra Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics pays -- of its earnings as a dividend. Kestra Medical Technologies pays out -1.99% of its earnings as a dividend.

  • Which has Better Financial Ratios BNGO or KMTS?

    Bionano Genomics quarterly revenues are $6.1M, which are larger than Kestra Medical Technologies quarterly revenues of --. Bionano Genomics's net income of -$44.2M is higher than Kestra Medical Technologies's net income of --. Notably, Bionano Genomics's price-to-earnings ratio is -- while Kestra Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.09x versus 22.62x for Kestra Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNGO
    Bionano Genomics
    0.09x -- $6.1M -$44.2M
    KMTS
    Kestra Medical Technologies
    22.62x -- -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

5 Investors to Follow Other Than Warren Buffett
5 Investors to Follow Other Than Warren Buffett

There is no doubt that Warren Buffett is one of…

Is BYD a Threat To Tesla Shareholders?
Is BYD a Threat To Tesla Shareholders?

BYD (OTC:BYDDY) has rocketed to the top of China’s booming…

CVX Vs XOM Stock, Which Energy Play Is Best?
CVX Vs XOM Stock, Which Energy Play Is Best?

Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Buy
99
DAVE alert for May 9

Dave [DAVE] is up 3.22% over the past day.

Buy
52
QDEL alert for May 9

QuidelOrtho [QDEL] is up 0.25% over the past day.

Buy
61
TPC alert for May 9

Tutor Perini [TPC] is up 3.58% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock